NTII — Neurobiological Technologies Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.25m
- $26.35m
Annual income statement for Neurobiological Technologies, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
R2005 June 30th | 2006 June 30th | 2007 June 30th | 2008 June 30th | 2009 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.1 | 12.3 | 17.7 | 14.8 | 26.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 28.3 | 40.3 | 33.3 | 33.2 | 23.9 |
| Operating Profit | -25.2 | -27.9 | -15.6 | -18.5 | 2.48 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -25 | -27.5 | -14.1 | -16.3 | 3.12 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -25 | -27.8 | -14.1 | -16.3 | 3.12 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -25 | -27.8 | -14.1 | -16.3 | 3.12 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -25 | -27.8 | -14.1 | -16.3 | 3.12 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.25 | -4.01 | -3.26 | -0.748 | 0.161 |
| Dividends per Share |